Intercept to Present at the J.P. Morgan Healthcare Conference
NEW YORK, Jan. 10, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.
(Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused
on the development and commercialization of novel bile acid therapeutics to
treat chronic liver and intestinal diseases, today announced that Mark
Pruzanski, M.D., President and Chief Executive Officer, will present at the
32^nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday,
January 15, 2014 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). A live
webcast of the company's presentation will be available on the "Events"
section of Intercept's investor website at http://ir.interceptpharma.com. A
replay of the presentation will also be archived and available on Intercept's
website for 2 weeks.
Intercept is a biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat orphan and more prevalent
liver diseases utilizing its expertise in bile acid chemistry. The company's
lead product candidate, obeticholic acid (OCA), is a bile acid analog and
first-in-class agonist of the farnesoid X receptor (FXR). OCA is being
developed for a variety of chronic liver diseases including primary biliary
cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), portal hypertension,
bile acid diarrhea and primary sclerosing cholangitis (PSC). OCA has received
orphan drug designation in both the United States and Europe for the treatment
of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan and
China, where it has out-licensed the product candidate to Dainippon Sumitomo
Pharma. For more information about Intercept, please visit the Company's
website at: www.interceptpharma.com.
CONTACT: Barbara Duncan
Press spacebar to pause and continue. Press esc to stop.